DGAP-News

MOLOGEN AG: First patient enrolled in TEACH study to treat HIV patients with MGN1703 - Seite 2

range of infections and diseases. HIV remains a serious worldwide health
issue. According to estimates by WHO and UNAIDS (United Nations Programme
on AIDS) 35 million people worldwide were living with HIV at the end of
2013. Some 2.1 million people became newly infected in that same year, and
1.5 million died as a result of HIV-related causes globally.

About MGN1703
MGN1703 is an innovative DNA-based TLR9 agonist developed by MOLOGEN that
broadly activates the immune system. This activation can be utilized to
enable the immune system to increase the recognition and combat of cancer
cells. Due to this mechanism of action, it is predicted that MGN1703 can be
applied to a number of diseases.

MOLOGEN AG
MOLOGEN AG is a biotechnology company specialized in the research and
clinical development of cancer immune therapies and DNA vaccines against
infectious diseases.

The cancer immune therapy MGN1703 is the company's lead product and
best-in-class TLR9 agonist. It is currently developed for first-line
maintenance treatment of colorectal cancer (pivotal randomized trial) and
small cell lung cancer (randomized controlled trial). A second
clinical-stage product is MGN1601, a therapeutic vaccination for the
treatment of renal cancer. A phase I/II clinical study has already been
completed successfully.

For more information on the trials please visit www.clinicaltrials.gov.

With unique, patented technologies and innovative products, MOLOGEN is
pioneering immune therapies.

MOLOGEN AG is a publicly listed company, headquartered in Berlin. The
shares (ISIN DE0006637200) are listed in the Prime Standard of the German
Stock Exchange.

www.mologen.com


Memberships in associations:
Biotechnologieverbund Berlin-Brandenburg (bbb) e.V. | BIO Deutschland e.V.
| DECHEMA - Society for chemical technology and biotechnology e.V. |
German industrial association of biotechnology (DIB) | Association for
the Promotion of Science and Humanities in Germany | Association of
German biotechnology companies (VBU) | Association of researching
manufacturers of pharmaceuticals e.V. (VFA) | Association of the chemical
industry e.V. (VCI)

MIDGE(R), dSLIM(R), EnanDIM(R) and MOLOGEN(R) are registered trademarks of
MOLOGEN AG.

Contact
Claudia Nickolaus
Head of Investor Relations & Corporate Communications